Biological context {#Sec1}
==================

Immunoglobulin G (IgG) is a multifunctional glycoprotein composed of an Fc region and two Fab regions, which are connected through the hinge region (Yamaguchi et al. [@CR24]). The Fab regions recognize and capture specific antigens, while the Fc region recruits complements and its cognate receptors, Fcγ receptors (FcγRs), and offers acceptor sites for bacterial proteins including protein A and protein G. The Fc region has a homodimeric structure comprising the C-terminal halves of the heavy chains, each composed of the C~H~2 and C~H~3 domains. The C~H~2 domain possesses a conserved *N*-glycosylation site, Asn297, at which a biantennary complex-type oligosaccharide is expressed with microheterogenieties characterized by the presence and absence of the non-reducing terminal galactose, fucose, sialic acid, and bisecting *N*-acetylglucosamine residues.

The effector function of IgG critically depends on *N*-glycosylation in the Fc region. The outer carbohydrate moieties govern the structural integrity of the FcγR-binding site of IgG, while the core fucosylation impairs antibody-dependent cellular cytotoxicity because of its negative steric effect against IgG interaction with FcγRIII (Ferrara et al. [@CR3]; Krapp et al. [@CR14]; Mizushima et al. [@CR19]; Yamaguchi et al. [@CR23]). Hence, the Fc glycoforms are now considered as a crucial factor in the design and production of therapeutic antibodies in biopharmaceutical fields (Berkowitz et al. [@CR1]; Jiang et al. [@CR5]).

NMR spectroscopy offers unique tools for characterizing the conformational dynamics and intermolecular interactions of IgG-Fc in solution (Kato et al. [@CR6], [@CR8], [@CR10]; Kim et al. [@CR12]; Latypov et al. [@CR15]). We developed protocols for uniform and amino acid-selective stable isotope labeling of an IgG glycoprotein and its functional fragments, using mammalian expression systems (Kato et al. [@CR11]; Yamaguchi and Kato [@CR21]). Based on partially (approximately 66 %) achieved spectral assignments (Yamaguchi et al. [@CR23]), we previously reported NMR analytical results to characterize the *N*-glycosylation-dependent conformational changes of human IgG1-Fc and its interaction with a specific RNA aptamer (Matsumiya et al. [@CR17]; Miyakawa et al. [@CR18]; Yamaguchi et al. [@CR23]).

In an extension of these studies, we herein report NMR assignments of the glycosylated version of Fc fragment (*M*r 53 kDa) cleaved from a chimeric antibody with human IgG1 constant regions that was expressed by Chinese hamster ovary (CHO) cells with uniform ^13^C- and ^15^N-labeling.

Methods and experiments {#Sec2}
=======================

The CHO/DG44 cell line (Urlaub1980) was kindly provided by Dr. Lawrence Chasin (Columbia University, NY). An anti-CCR4 chimeric antibody (designated KM3060), with human IgG1/κ constant regions, was produced in a CHO cell line as described previously (Yamaguchi and Kato [@CR21]; Yamaguchi et al. [@CR23]). The CHO cells were cultivated using the Nissui NYSF 404 medium supplemented with 2 % dialyzed fetal bovine serum. At the final stage of cell culture, the medium was replaced with an isotopically labeled one with 2 % dialyzed fetal bovine serum. Uniformly ^15^N/^13^C-labeled IgG1 was prepared using a modified Nissui NYSF 404 medium (supplemented with 2 % dialyzed fetal bovine serum) in which glucose, sodium pyruvate, succinic acid, and amino acids were replaced by 1 g/L \[^15^N/^13^C\]algal amino acid mixture, 2 g/L D-\[^13^C~6~\]glucose, 110 mg/L \[^13^C~3~\]pyruvic acid sodium salt, 59 mg/L \[^13^C~4~\]succinic acid, 149 mg/L L-\[^13^C~6~,^15^N~4~\]Arg·HCl, 42.5 mg/L L-\[^13^C~4~,^15^N~2~\]Asn·H~2~O, 24 mg/L L-\[^13^C~3~,^15^N\]Cys, 450 mg/L L-\[^13^C~5~,^15^N~2~\]Gln, 17 mg/L L-\[^13^C~6~,^15^N~3~\]His·HCl·H~2~O, 27 mg/L L-\[^13^C~9~,^15^N\]Tyr, and 7 mg/L L-\[^13^C~11~,^15^N~2~\]Trp. Amino acid-selective labeling of IgG1 was performed using the modified Nissui NYSF 404 medium (supplemented with 2 % dialyzed fetal bovine serum) in which selected amino acid components were substituted with isotopically labeled analogs, as described previously (Kato et al. [@CR6], [@CR7], [@CR9]; Kim et al. [@CR13]). After cell growth, the supernatant was purified using an Affi-gel protein A column (GE Healthcare Bio-Sciences), as described previously (Yamaguchi et al. [@CR22]). The Fc fragment of IgG1 was prepared by papain digestion, performed at 37 °C for 12 h in 75 mM sodium phosphate buffer (pH 7.0) containing 75 mM NaCl, and 2 mM EDTA. The protein concentration was 10 mg/ml, and the ratio of papain/IgG1 was 1:50 (w:w). The digestion products were loaded onto an Affi-gel protein A column. To prepare IgG1-Fc exhibiting a homogeneous *N*-glycan, GlcNAcβ1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc, the Fc fragment was treated with a recombinant *Streptococcus pneumoniae* β1,4-galactosidase (CALBIOCHEM), according to the literature (Yamaguchi et al. [@CR23]).

For NMR measurements, the Fc fragment was dissolved in 0.5 ml of 5 mM sodium phosphate buffer (pH 6.0) containing 50 mM NaCl and 10 % (v/v) D~2~O. NMR spectra were acquired at 42 or 52 °C using DMX500 (Bruker BioSpin), AVANCE800 (Bruker BioSpin), and ECA-920 (JEOL) spectrometers. Chemical shifts of ^1^H were referenced to DSS (0 ppm), and ^13^C and ^15^N chemical shifts were referenced indirectly using the gyromagnetic ratios of ^13^C, ^15^N, and ^1^H (*γ*^13^C/*γ*^1^H = 0.25144952; *γ*^15^N/*γ*^1^H = 0.10132905).

Backbone resonance assignments were made on the basis of 2D ^1^H--^15^N HSQC spectral data of uniformly or selectively ^13^C/^15^N-labeled IgG1-Fc, and 3D spectral data obtained with the following experiments: HNCA, HNCO, HN(CA)CO, CBCA(CO)NH, and HNCACB. All NMR data were processed using NMRPipe software (Delaglio et al. [@CR2]), and analyzed with SPARKY (Goddard and Kneller [@CR4]) and CcpNmr (Vranken et al. [@CR20]) software.

Assignments and data deposition {#Sec3}
===============================

Figure [1](#Fig1){ref-type="fig"} shows the ^1^H--^15^N HSQC spectrum of human IgG1-Fc. Although the use of a mammalian expression system is mandatory for preparing antibodies with physiological glycosylation, uniform deuteration of the glycoprotein is not facile in such a system (Liu et al. [@CR16]). Hence, we established spectral assignments based on the triple resonance spectral dataset recorded at a higher temperature, i.e. 52 °C, complemented with HSQC spectral data obtained by amino acid-selective ^13^C/^15^N-labeling. Chemical shift assignments were made for protein backbone resonances: Cα (99 %), Cβ (84 %), CO (80 %), HN (99 %), and N (99 %) (except for N of prolines). The spectral assignments at lower temperatures could be extrapolated by observing progressive spectral changes, depending on temperature, as exemplified by the spectrum at 42 °C (Supplemental Fig.1). The present spectral assignments indicate that a cluster of amino acid residues in the vicinity of the *N*-glycans, i.e. Gln295-Thr299 exhibit significant chemical shift differences in comparison with the previously reported assignments of human Fc produced in Escherichia coli (Liu et al. [@CR16]).Fig. 1^1^H--^15^N HSQC spectrum of uniformly ^13^C, ^15^N-labeled IgG-Fc recorded at 52 °C. Backbone assignments are annotated by the resonance peaks with one-letter amino acid codes and the sequence numbers. Side-chain resonances corresponding to NH~2~ amides are connected by *horizontal lines*

The assignments for the ^1^H, ^13^C, and ^15^N backbone resonances of human IgG1-Fc have been deposited in the BioMagResBank database (<http://www.bmrb.wisc.edu>) under the accession number 25224.
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